1. Home
  2. SONN

SONN

Sonnet BioTherapeutics Holdings Inc.

Logo Sonnet BioTherapeutics Holdings Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-23-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Founded: N/A Country:
N/A
Employees: N/A City: PRINCETON
Market Cap: 5.4M IPO Year: N/A
Target Price: $61.47 AVG Volume (30 days): 103.9K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -9.87 EPS Growth: N/A
52 Week Low/High: $1.08 - $26.40 Next Earning Date: 01-01-0001
Revenue: $129,176 Revenue Growth: -49.81%
Revenue Growth (this year): -19.26% Revenue Growth (next year): N/A

Share on Social Networks: